Scopus Biopharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing transformational therapeutics for serious diseases with significant unmet medical needs. The company's primary focus is on immuno-oncology, aiming to improve outcomes for patients with treatment-resistant cancers. Scopus Biopharma's innovative Duet Platform consists of a suite of bifunctional oligonucleotides that both activate antigen-presenting cells within the tumor microenvironment and relieve tumor-induced immunosuppression, thereby jump-starting T cell-mediated immune responses. The platform includes three candidates—DUET-01, DUET-02, and DUET-03—which combine a toll-like receptor 9 (TLR9) agonist with a STAT3 inhibitor, targeting various blood and solid tumors, including B-cell non-Hodgkin lymphoma and cancers such as prostate and kidney. Headquartered in New York and founded in 2017, Scopus Biopharma leverages collaborations and licensing agreements with leading research institutions to bring groundbreaking therapies from the laboratory to the clinic, positioning itself as a key innovator in the biopharmaceutical and immuno-oncology landscape.